Artiva Biotherapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Artiva Biotherapeutics, Inc. (ARTV) reported Increase (Decrease) in Accrued Liabilities of $17.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.02M.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.00M.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.37M.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.12M, a 63.93% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $2.00M.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$659.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$912.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.00K 10-Q · filed 2026-08-06 | $2.38M derived: sum of 3 quarters · filed 2026-08-06 | $3.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.00M 10-Q · filed 2026-05-08 | -$1.64M derived: sum of 2 quarters · filed 2026-05-08 | -$519.00K derived: sum of 3 quarters · filed 2026-05-08 | -$1.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.48M derived: sum of 2 quarters · filed 2026-03-10 | $2.93M derived: sum of 3 quarters · filed 2026-08-06 | $2.00M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $569.00K derived: sum of 2 quarters · filed 2026-08-06 | -$362.00K 10-Q · filed 2025-11-12 | -$1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.48M 10-Q · filed 2026-08-06 | -$2.47M derived: sum of 3 quarters · filed 2026-08-06 | $629.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$931.00K 10-Q · filed 2026-05-08 | -$1.92M derived: sum of 2 quarters · filed 2026-05-08 | $1.18M derived: sum of 3 quarters · filed 2026-05-08 | $1.45M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.11M derived: sum of 2 quarters · filed 2026-03-10 | $2.38M derived: sum of 3 quarters · filed 2026-03-10 | -$659.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.38M derived: sum of 2 quarters · filed 2025-11-12 | $333.00K 10-Q · filed 2025-11-12 | $476.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$2.77M 10-Q · filed 2025-08-06 | -$2.63M derived: sum of 3 quarters · filed 2025-08-06 | -$2.98M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$3.04M 10-Q · filed 2025-05-08 | -$2.90M derived: sum of 2 quarters · filed 2025-05-08 | -$3.26M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$216.00K derived: sum of 2 quarters · filed 2025-03-24 | -$912.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$359.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.05M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$696.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |